BSI 04702
Alternative Names: BSI-04702; R-4702Latest Information Update: 19 Jul 2024
At a glance
- Originator Biosion
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action TROP2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 31 May 2024 Pharmacodynamics data from preclinical trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 12 Aug 2022 OBI Pharma plans to file an IND application for Solid tumours in the second half of 2023 (Biosion pipeline, August 2022)
- 13 Dec 2021 OBI Pharma in-licenses BSI 04702 from Biosion